StockNews.com Begins Coverage on Aethlon Medical (NASDAQ:AEMD)

Stock analysts at StockNews.com began coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a report released on Friday. The brokerage set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Aethlon Medical in a research report on Friday, November 15th.

Aethlon Medical Price Performance

Shares of NASDAQ:AEMD opened at $0.80 on Friday. The company has a market cap of $11.17 million, a P/E ratio of -0.28 and a beta of 1.61. The company’s fifty day moving average is $0.46 and its two-hundred day moving average is $0.43. Aethlon Medical has a 12-month low of $0.24 and a 12-month high of $2.23.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.